Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares OutstandingShort-Term Debt issuances
Ratios

Bristol Myers Squibb (BMYMP) EBIAT (2016 - 2025)

Historic EBIAT for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to $1.1 billion.

  • Bristol Myers Squibb's EBIAT rose 140694.44% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.1 billion, marking a year-over-year increase of 17898.21%. This contributed to the annual value of $7.1 billion for FY2025, which is 17884.44% up from last year.
  • Per Bristol Myers Squibb's latest filing, its EBIAT stood at $1.1 billion for Q4 2025, which was up 140694.44% from $2.2 billion recorded in Q3 2025.
  • Bristol Myers Squibb's 5-year EBIAT high stood at $2.5 billion for Q1 2025, and its period low was -$11.9 billion during Q1 2024.
  • In the last 5 years, Bristol Myers Squibb's EBIAT had a median value of $1.6 billion in 2022 and averaged $976.0 million.
  • In the last 5 years, Bristol Myers Squibb's EBIAT plummeted by 62540.8% in 2024 and then skyrocketed by 140694.44% in 2025.
  • Over the past 5 years, Bristol Myers Squibb's EBIAT (Quarter) stood at $2.4 billion in 2021, then fell by 14.63% to $2.0 billion in 2022, then decreased by 12.99% to $1.8 billion in 2023, then tumbled by 95.91% to $72.0 million in 2024, then skyrocketed by 1406.94% to $1.1 billion in 2025.
  • Its EBIAT stands at $1.1 billion for Q4 2025, versus $2.2 billion for Q3 2025 and $1.3 billion for Q2 2025.